'Worrying' number of teens lose disability benefits
Teenagers with incurable conditions are among hundreds a week being stripped of disability benefits after their 16th birthdays.
Nearly a third of those who received Disability Living Allowance (DLA) in childhood had claims for Personal Independence Payment (PIP) rejected when trying to move to the adult benefit, BBC analysis has found.
Disability charity Scope said a "complex, adversarial and difficult to navigate" system contributed to the rejections.
With widespread benefits reform proposals expected within weeks, Prime Minister Keir Starmer this week called the current system "unsustainable, indefensible and unfair".
The conditions most likely to result in a refused claim were those that may be managed more successfully by an adult than a child, like diabetes or asthma, experts said.
But among those to have had claims rejected since PIP's introduction in 2013 are thousands living with life-changing conditions including cancer, blindness, psychosis, deafness and epilepsy.
The 124,000 young people affected since then include Holly Crouch, who said the decision by the Department for Work and Pensions (DWP) had left her feeling "like a burden" when "nothing changed but my age".
She said she had been refused PIP when she applied as a teenager, despite providing evidence from specialists saying she was at risk of sudden, life-threatening epileptic seizures.
Miss Crouch said the DWP had decided she no longer needed support because she had been seizure-free for several weeks.
Holly's parents subsequently lost their Carers' Allowance payments but still have to provide constant supervision.
The 21-year-old from East Sussex said: "My condition has not magically disappeared and I'm not faking this.
"Everything was taken so quickly and I felt angry, neglected and like I hadn't been believed. It was so hard to deal with."
Holly said she had lost three jobs because of her epilepsy and had to "rely on others for everything" without PIP.
"I'll never feel like an adult as I can't do things everyone else is able to, like drive or work," she said. "My parents even have to be there when I shower or boil a kettle as I could have a seizure.
"I understand there could be changes to conditions, but that's what reviews are for - you shouldn't just have your money stopped at 16 when you are not old enough for the process."
James Taylor, Scope's executive director of strategy, said the number of young people losing out on financial support was "worrying".
He called on the government to work with disabled people and "fix our broken welfare system".
Starmer says benefit system unfair and indefensible
How big is the welfare budget and where might cuts fall?
Access All: Disability News and Mental Health
Three-quarters of those deemed ineligible for PIP had failed the DWP's points-based assessment, according to BBC analysis.
While appeals can be lodged and some people do receive higher awards under PIP than DLA, the BBC heard of young people refused benefits despite the significant impact of their disabilities on daily life.
They include:
Several who reportedly failed the assessment because they were able to work part-time or attend school or college
A teenager with Down's syndrome who told his PIP assessor he could do everything he was quizzed about, but did not explain the intensive support he needed to do so
A teenager with learning difficulties who said he could cook for himself but did not mention he had broken several microwaves in trying to do so
Concerns were repeatedly raised about PIP assessors lacking knowledge of specific conditions and decisions being taken without recourse to medical evidence or contacting those involved in a claimant's care.
Disability and welfare rights organisations say the system results in wrongful decisions, with DWP outcomes frequently overturned at tribunal.
The Royal National Institute for Blind People, Epilepsy Society, the National Autistic Society and Contact are among those calling for rapid reform.
• Personal Independence Payment is a benefit for over-16s with long-term physical or mental health conditions
• It is not means-tested and aims to fund the extra living costs associated with having a disability
• Assessments focus on how capable someone is of living independently and use a series of questions about daily activities
• Points are awarded based on the individual's abilities and what help they need
• Those points are added up to determine whether the threshold for a claim is met
• A third party - like a parent or carer - can apply to represent someone without the capacity to do so themselves
A recent Resolution Foundation report found the number of young people in receipt of disability benefits falls significantly between the ages of 15 and 17.
The think-tank said the failure to qualify - or apply for - PIP was leaving many "facing a financial cliff-edge" as they approached adulthood.
Fightback4Justice, which advocates for disabled people in the welfare system, has called for the process to be more transitional.
Its founder, Michelle Cardno, said: "Young people are being treated as adults from the day they reach 16, when most do not understand the system."
Sally Donley acted for her son Euan Hawes when he was invited to transition from DLA to PIP.
She says she spent two hours talking with an assessor about the impact of Euan's disabilities, which include autism, obsessive compulsive disorder and sensory processing disorder.
"His assessment was with a nurse who had no background in his issues and he ended up only scoring points for not mixing with others," said Ms Donley, from Hampshire.
"Because I said he could cook eggs in the microwave, they said he could cook for himself and they said he goes to college independently - but it's a specialist college he travels an hour in a taxi to."
Euan's claim was refused, but the decision was eventually overturned and he was granted PIP's highest rates when Ms Donley took the DWP to a tribunal.
"The stress this puts on families is horrendous and cruel," she said. "You have parents trying to care for children with disabilities and they're having to take hours to gather evidence for court appeals.
"They need to listen and they need to look at medical evidence."
The government is being called upon to bring the rest of the UK in line with Scotland, where the transition to adult disability benefits can now take place at 18.
Ms Donley, who supports those calls, added: "Euan's 18 now and I'm still fighting for him. I know I'll be fighting for him until my last breath."
A DWP spokesman said: "Building on our Get Britain Working White Paper, we will bring forward proposals for reforming the health and disability benefits system within weeks, so that it provides children, young adults and their families with the support they need in a way that's fair on the taxpayer, and helps those who can work secure employment."
More about this story
The Shared Data Unit makes data journalism available to news organisations across the media industry, as part of a partnership between the BBC and the News Media Association.
Read more about the Local News Partnerships here.
Children face 'lifetime cost' of council crisis
Deadly new drugs found in fake medicines in the UK
Burning rubbish now UK's dirtiest form of power
DWP: Personal Independence Payment
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
'I feel that I am not valued as a carer'
A woman whose 11-year-old son has complex disabilities says she feels under valued as a carer. Speaking during Carers Week, Becky Pain-Tolin, from Gloucestershire, said the care system was "diabolical" and "incredibly underfunded". Ms Pain-Tolin, whose father has advanced vascular dementia and lives in a care home, said: "Unpaid carers deserve more, my father deserves more and my son deserves more." A spokesperson for the Department for Work and Pensions (DWP) said they understood "the huge difference carers make, as well as the struggles so many face". They said the government increased the Carer's Allowance earnings threshold by £45 a week to £196, which would benefit more than 60,000 carers by 2029/30. Ms Pain-Tolin's son needs two-to-one care at all times and three-to-one care when in the community. More news stories for Gloucestershire Listen to the latest news for Gloucestershire Without the support she gets from Gloucestershire County Council, the 42-year-old said she would be on the verge of a breakdown. Ms Pain-Tolin said she worked 12 hours a week, but this meant she was "really pushing" what she could manage, which had impacted her mental health. "'I do not have much of a life that does not involve caring," she said. The DWP said it had launched an independent review into social care, which would "include exploring the needs of unpaid carers who provide vital care and support". According to Gloucestershire County Council, there were 52,000 people listed as unpaid carers in the county in the 2021 Census. But Lisa Walker, the regional manager of Gloucestershire Carers Hub, said she thought the figure was significantly higher because unpaid carers frequently do not identify themselves as such. "I am an unpaid carer myself, I didn't even recognise that I was one until a colleague pointed it out," she said. Ms Walker said there were a number of inequalities experienced by people working as unpaid carers. "One of the biggest things is health and people not prioritising their own wellbeing. "There are also issues around health professionals and GPs recognising that people have another additional role. "There are issues around working. Approximately 600 people a day leave work because of care responsibilities. "There is also people's mental wellbeing and accessing social activities - those are just some of the inequalities that carers face," she added. The theme for this year's carers week, which is running from Monday to Friday, is caring about equality. Gloucestershire Carers Hub hosted an event on Monday to provide resources and support for those in need. Follow BBC Gloucestershire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630. Adult social care service 'requires improvement' SEND families being let down by authority and NHS County has 6,000 young carers 'unaccounted for' Gloucestershire County Council Department for Work and Pensions
Yahoo
a day ago
- Yahoo
King Charles Attends Trooping the Colour Amid Cancer Treatment
The annual Trooping the Colour parade celebrates the British monarch's birthday—even if their birthday isn't in June. Charles, today, is attending his third Trooping as King, ahead of his 76th birthday this November. Like last year, King Charles did not ride on horseback in the parade, instead choosing to ride in a carriage alongside Queen Camilla. Trooping the Colour is taking place as King Charles continue to receive treatment for cancer. Buckingham Palace has never revealed what type of cancer the king has, only specifying it is not prostate cancer, and has shared infrequent updates on his health since the initial diagnosis announcement last February. This past March, the King was briefly hospitalized, according to the Palace, when he experienced side effects 'following scheduled and ongoing medical treatment for cancer.' Prince Harry also recently sparked concern about Charles's health when he commented to the BBC that he doesn't know how much longer his father has to live. 'He won't speak to me because of this security stuff. But it would be nice to reconcile,' the Duke of Sussex revealed. Yet, in May, a senior royal aide said the King is dealing 'incredibly well' with cancer, adding, 'The thing you learn about this illness is that you just manage it and that's what he does. Medical science has made incredible advances and I genuinely see no difference in him. As long as you just do what the doctors say, just live your life as normal as possible... that's exactly what he is doing.' You Might Also Like 12 Weekend Getaway Spas For Every Type of Occasion 13 Beauty Tools to Up Your At-Home Facial Game
Yahoo
2 days ago
- Yahoo
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy PolTREG established Immuthera ( in Delaware to expand its presence in the U.S. market. A Pre-IND application was submitted to the FDA. The Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on PolTREG's Pediatric Investigation Plan (PIP) for PTG-007 in pre-symptomatic type 1 diabetes (Stage 1). Gdańsk, Poland – 13 JUNE 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, announces that it has established a wholly owned subsidiary, Immuthera, a United States C Corporation, in the state of Delaware. This is a further step by PolTREG to deepen its entry into the U.S. market. 'Over recent years, PolTREG has created a platform for the development of multiple cellular therapies: polyclonal Tregs, CAR-TREGs, mulit-eidited/allogeneic CAR-Tregs, antigen-specific Tregs, and mRNA immunotherapies, all informed by our clinical experience. To fully leverage our potential, we are focusing on the execution our growth strategy in the American market by systematically bringing existing therapies, and exploring new assets into the US. We have established partnerships with several renowned entities such as Noble Capital Markets, Inc., for strategic and financial advisory services. We have also formed a strategic cooperation with the Swiss company Antion Biosciences to develop the next generation of allogeneic TREG therapies' said Prof. Piotr Trzonkowski, CEO of PolTREG. 'This expands PolTREG's project pipeline and enhances the company's attractiveness to potential strategic partners. Additionally, we with the U.S. company Kinexum Services LLC for strategic advisory regarding Immuthera's interactions with the FDA and the registration of TREG therapies in the United States. We submitted our Pre-IND meeting request to the FDA in mid-May,' added Prof. Piotr Trzonkowski. PolTREG is currently in discussions with leading American academic and clinical centers to establish collaborations and evaluate new technologies Immuthera has also begun the process of building a world-class Scientific Advisory Board comprised of globally recognized leaders in the Autoimmune and Neuroinflammatory disease. In support of PolTREG and the launch of Immuthera, Dr. Dan Shelly, Chief Business Development Officer, and Dr. Mariusz Jablonski, Chief Business Officer, will participate in the upcoming BIO International Convention 2025, taking place from June 16–19 in Boston. At BIO Drs. Shelly and Jablonski will be promoting PolTREG's current clinical and developmental pipeline while also speaking to potential partners, collaborators, and investors for Immuthera. In May, the Paediatric Committee (PDCO) of the European Medicines Agency issued a positive opinion on the Pediatric Investigation Plan (PIP) for PolTREG's investigational somatic cell therapy product, polyclonal Treg lymphocytes (PTG-007), which is aimed to prevent symptomatic type 1 diabetes in children. The PDCO's positive opinion is based on PolTREG's original preTreg clinical trial protocol, initiated in October 2024, enrolling children aged 6–16 years with Stage 1 type 1 diabetes. In its assessment, the committee recommended broadening the eligible population to include patients aged 3–18 years suggesting that the agency believes this therapy is extremely safe. This positive opinion paves the way for potential marketing authorization in the EU. To read more about the clinical trials PolTREG has completed, please click on: PolTREG manufactures its Treg therapeutics at its own GMP-certified manufacturing facility. It is the first company in the world to have administered Treg therapies to patients, and, under a hospital exemption valid in Poland, the first company to start receiving revenues from a Treg therapeutic for autoimmune disease. Its GMP manufacturing facility is one of Europe's largest and most advanced, boasting over 2,100 sqm of laboratory space, including 15 production lines. PolTREG has the option to substantially expand the facility to accommodate manufacturing of next-generation engineered therapies and cell therapies. It can ship its wide range of cellular therapy products across Europe within 24 hours. About PolTREG PolTREG is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs). Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership. PolTREG has established a robust platform encompassing a wide range of cell therapy approaches, including polyclonal TREG, CAR-TREG, allogeneic TREG, antigen-specific TREG, and TCR-TREG therapies. About Immuthera Immuthera is pioneering novel cell-based therapies for clinical development in the United States and Canada. Immuthera will be clinically developing assets initially developed by PolTREG under the US FDA regulatory framework. Immuthera will have full access to PolTREG's Research and Development capabilities along with the ability to explore novel modalities developed by US Institutions. Immuthera is currently seeking investment to pursue the manufacture and clinical development of these assets in the United States. For more information please visit For further information please contact:PolTREG Piotr TrzonkowskiChief Executive Officerir@ 512 532 401 Important information The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company's actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.